Navigation Links
AdvanDx's PNA FISH(TM) Test Shown to Reduce Mortality by 42% for Patients With Hospital-Acquired Enterococcus faecium Bloodstream Infections
Date:10/22/2008

Two Days Faster Test Results Enable Physicians to Direct Earlier, Effective Antimicrobial Therapy for Patients with Drug Resistant Hospital-Acquired

Infections and Save Lives(1)

WOBURN, Mass., Oct. 22 /PRNewswire/ -- AdvanDx today announced that a new medical study demonstrated use of AdvanDx's PNA FISH(TM) test reduced mortality by 42% for patients with highly drug resistant Hospital-Acquired Enterococcus faecium bloodstream infections (BSI's). In addition, the study demonstrated that PNA FISH reduced the time to reporting of laboratory identification results for all enterococcal BSI's by 2.6 days and reduced time to appropriate antimicrobial therapy for E. faecium BSI's by 1.8 days. The study was undertaken by clinicians at the University of Maryland Medical Center (UMMC) in Baltimore, Maryland and published in the latest issue of Antimicrobial Agents and Chemotherapy.(1)

Bloodstream infections due to Enterococcus bacteria, predominantly Enterococcus faecalis and E. faecium, are often acquired while patients are in the hospital and can lead to increased mortality, longer hospital stays and increased healthcare costs. The infection is initially diagnosed when a culture of the patient's blood turns positive with Gram-positive cocci in pairs and chains (GPCPC), indicative of enterococci and/or streptococci. Because conventional laboratory identification methods can take 48 hours or longer and early antimicrobial therapy is crucial to ensure positive patient outcomes, physicians often prescribe broad-spectrum antibiotics such as vancomycin to cover the patient. However, this may lead to the administration of inadequate or inappropriate antibiotic treatment as E. faecium is often resistant to both vancomycin (VRE - vancomycin-resistant enterococci) and penicillin-based drugs such as ampicillin while E. faecalis is often susceptible to ampicillin. PNA FISH delivers rapid, molecular identification of E. faecalis and other enterococci, including E. faecium, directly from GPCPC positive blood cultures in hours instead of days. As a result, laboratories can provide faster information that enables clinicians to select effective antibiotic therapy sooner for patients afflicted with enterococcal bloodstream infections.(1)

The study included 224 patients with hospital-acquired enterococcal bloodstream infections; 112 patients before the PNA FISH test was implemented (Pre-PNA FISH group) and 112 after implementation (PNA FISH group). A treatment algorithm based on the rapid PNA FISH results was developed and implemented by the hospital's antimicrobial management team. Patients with E. faecalis by PNA FISH were to be given ampicillin, while patients with other enterococci, including E. faecium, and at "high risk" for VRE were to be given linezoid, a newer anti-VRE antibiotic. At the end of the study, data on characteristics, therapy and outcomes between the Pre-PNA FISH and PNA FISH patients groups were compared.(1)

Significant UMMC Study Data (Pre-PNA FISH vs. PNA FISH Groups)(1)

-- More than 88% of all E. faecium were resistant to vancomycin (VRE) and

100% were resistant to ampicillin

-- 84% of initial empirical antimicrobial therapy for patients with E.

faecium BSI's was inadequate

-- 2.6 days reduction in time to laboratory identification results in PNA

FISH group

-- 1.8 days reduction in time to appropriate antimicrobial therapy for E.

faecium in PNA FISH group

-- 42% reduction in 30-day mortality rates for patients with E. faecium in

PNA FISH group

-- PNA FISH Sensitivity, Specificity, Positive Predictive Value and

Negative Predictive Value shown to be 100% compared to conventional

methods

"Use of PNA FISH in conjunction with a treatment algorithm led to earlier identification of the Enterococcus species for patients with hospital-acquired enterococcal bloodstream infections and the earlier initiation of effective antimicrobial therapy for patients with hospital-acquired E. faecium bloodstream infections," said Dr. Graeme Forrest, Division of Infectious Diseases, University of Maryland Medical Center and lead author of the study.

"We are very excited to see the results from the University of Maryland Medical Center study. Not only do they show that PNA FISH significantly speeds up species identification results from the lab, but also that using the results to tailor therapy at an earlier stage in bloodstream infections can significantly improve patient care and outcomes," said Thais T. Johansen, President and CEO of AdvanDx. "If we extrapolate the data to the rest of the country, PNA FISH could help ensure that all of the 18,000 patients with hospital-acquired enterococcal bloodstream infections receive effective antibiotic therapy as early as possible and help save close to 2,000 lives. In essence, implementing PNA FISH and providing rapid results to clinicians could be more beneficial than any new antibiotic to treat the infections," Johansen added.

About Bloodstream Infections

Every year, 350,000 patients contract bloodstream infections, causing over 90,000 unnecessary deaths and significant costs to the healthcare system. The infection is detected when a culture of the patient's blood (i.e. a blood culture) turns positive with bacteria and yeast. Rapid and accurate identification of the specific infecting pathogen is crucial to ensure early and appropriate therapy and save patient lives.

About PNA FISH(TM)

PNA FISH is an easy-to-use and highly sensitive and specific fluorescence in situ hybridization (FISH) assay that uses PNA (peptide nucleic acid) probes to target species specific ribosomal RNA (rRNA) in live bacteria and yeast. The unique properties of the non-charged, peptide backbone of PNA probes enable the use of FISH assays in exceedingly complex sample matrixes, such as blood and blood cultures, and this in turn facilitates the development of very simple, yet very accurate tests that don't require the extensive sample preparation necessary for other nucleic acid technologies.

PNA FISH tests enable microbiology labs to provide rapid and accurate identification of bloodstream pathogens directly from positive blood cultures in hours instead of days. Clinical studies show that rapid identification of bloodstream pathogens using PNA FISH tests leads to more appropriate patient therapy that saves lives and reduces unnecessary antibiotic use, patient length of stay and hospital costs.

About AdvanDx

AdvanDx is the world's leading provider of advanced molecular diagnostic products for the prevention, diagnosis and treatment of life-threatening, bacterial infections. AdvanDx's easy-to-use products provide fast and accurate results that enable dramatic improvements in patient care and help to save lives and reduce hospital costs.

AdvanDx's products employ standard laboratory techniques and equipment to reduce startup, implementation, technician and maintenance time, while providing fast results without sacrificing accuracy. Major medical centers, reference labs, government institutions and community hospitals throughout the United States, Europe and Asia rely on AdvanDx products as integral parts of their medical care.
For more information visit http://www.AdvanDx.com

CONTACTS:

Company Contact: Media Inquiries:

Joen T. Johansen Joe Romano

Director of Marketing Partner

AdvanDx HighGround, Inc.

+1-339-227-4052 +1-781-939-5800 Ext 208

jtj@advandx.com jromano@highgroundinc.com

References:

(1) Forrest et al. Peptide nucleic acid fluorescent in situ

hybridization for hospital-acquired enterococcal bacteremia:

delivering earlier effective antimicrobial therapy. Antimicrob

Agents Chemother. 2008 Oct;52(10):3558-63.


'/>"/>
SOURCE AdvanDx
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AdvanDx Receives FDA 510(k) Clearance for Yeast Traffic Light PNA FISH(TM)
2. With the BEAUTIFUL Results, Procoralan* (ivabradine) is the First Antianginal Treatment Shown to Reduce Myocardial Infarction (Heart Attack) and Revascularisation in Stable Coronary Patients
3. Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over
4. Innovative Fosshield(R) Antimicrobial Technology Shown to Continuously Kill MRSA Superbug
5. EnrichMap Announces New Program To Reduce Medical Patient Noncompliance And Offers Healthcare Organizations A Limited Trial Test Opportunity
6. Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes
7. Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
8. Roche and Response Biomedical Corporation Aim to Reduce Vein-to-Brain Time with New Point-of-Care Cardiac Tests
9. Carbon hoofprint: Cows supplemented with rbST reduce agricultures environmental impact
10. Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
11. Studies Show USGI Medicals EndoSurgical Operating System(TM) Enables Incisionless Surgery to Reduce Gastric Pouch and Stoma After Gastric Bypass
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2017)... (PRWEB) , ... August 14, 2017 , ... The ... Trials event, which will take place on September 6, 2017 at the Marriott ... MD , Head of Experimental Medicine, Informatics, and Regulatory Strategy, Pfizer Innovative Research Lab, ...
(Date:8/11/2017)... ... August 11, 2017 , ... A staple in the community for more than ... important key elements including a new digital marketing strategy and updated logo. , As ... Miller has partnered with the South Texas Blood & Tissue Center for the month ...
(Date:8/11/2017)... ... August 11, 2017 , ... “There is an increasing ... alternatives to synthetic ingredients,” said Matt Hundt, President of Third Wave Bioactives. “Combining ... presence and know-how of Biorigin will allow us to bring truly novel fermented ...
(Date:8/10/2017)... ... August 09, 2017 , ... Teachers from three ... From August 14th through the 16th, the University City Science Center will kick ... of 2016, provides Philadelphia-based middle school educators an opportunity for professional development related ...
Breaking Biology Technology:
(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
(Date:3/27/2017)... N.Y. , March 27, 2017  Catholic ... Information and Management Systems Society (HIMSS) Analytics for ... EMR Adoption Model sm . In addition, CHS ... of U.S. hospitals using an electronic medical record ... for its high level of EMR usage in ...
Breaking Biology News(10 mins):